Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: A systematic review

Drug Metabolism and Disposition

Volumn 42, Issue 12, 2014, Pages 1991-2001

  Yu, Jingjing ^a   Ritchie, Tasha K ^a   Mulgaonkar, Aditi ^a,b   Ragueneau Majlessi, Isabelle ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ALOGLIPTIN; BAZEDOXIFENE PLUS CONJUGATED ESTROGEN; CANAGLIFLOZIN; CYTOCHROME P450 3A; DABRAFENIB; DIGOXIN; DOLUTEGRAVIR; ESLICARBAZEPINE ACETATE; FLUTEMETAMOL F 18; FLUTICASONE FUROATE PLUS VILANTEROL; FUMARIC ACID DIMETHYL ESTER; GADOTERATE MEGLUMINE; GLUCURONOSYLTRANSFERASE; IBRUTINIB; LULICONAZOLE; MACITENTAN; MIPOMERSEN; OBINUTUZUMAB; OSPEMIFENE; POMALIDOMIDE; RADIUM CHLORIDE RA 223; RIOCIGUAT; SIMEPREVIR; SOFOSBUVIR; TILMANOCEPT TC 99M; TRAMETINIB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VORTIOXETINE; DRUG;

AREA UNDER THE CURVE; DRUG DISPOSITION; DRUG INTERACTION; DRUG METABOLISM; DRUG TRANSPORT; FOOD AND DRUG ADMINISTRATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; PHARMACOGENETICS; REVIEW; SYSTEMATIC REVIEW; DRUG INACTIVATION; HUMAN; METABOLISM; PHYSIOLOGY; UNITED STATES;

DRUG INTERACTIONS; HUMANS; INACTIVATION, METABOLIC; PHARMACEUTICAL PREPARATIONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84910059806     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.060392     Document Type: Review

References (39)

1. Benet LZ (2010) Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. Basic Clin Pharmacol Toxicol 106:162-167.
2. Bruderer S, Aänismaa P, Homery MC, Häusler S, Landskroner K, Sidharta PN, Treiber A, and Dingemanse J (2012) Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J 14:68-78.
3. Chen G, Lee R, Højer AM, Buchbjerg JK, Serenko M, and Zhao Z (2013) Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig 33:727-736.
4. Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, Lai Y, Matsson P, Moss A, Nagar S, Rosania GR, et al.; International Transporter Consortium (2013) Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther 94: 126-141.
5. Fahmi OA, Kish M, Boldt S, and Obach RS (2010) Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. Drug Metab Dispos 38:1605-1611.
6. Falcão A, Pinto R, Nunes T, and Soares-da-Silva P (2013) Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. Epilepsy Res 106:244-249.
7. FDA (2013a) Package insert. ADEMPAS (Riociguat). FDA application NDA 204819.
8. FDA (2013b) Package insert. ANORO ELLIPTA (Umeclidinium and vilanterol). FDA application NDA 203975.
9. FDA (2013c) Package insert. APTIOM (Eslicarbazepine acetate. FDA application NDA 022416.
10. FDA (2013d) Package insert. BREO ELLIPTA (Fluticasone and vilanterol). FDA application NDA 204275.
11. FDA (2013e) Package insert. BRINTELLIX (Vortioxetine). FDA application NDA 204447.
12. FDA (2013f) Package insert. DOTAREM (Gadoterate meglumine). FDA application NDA 204781.
13. FDA (2013g) Package insert. DUAVEE (Conjugated estrogens and bazedoxifene). FDA application NDA 022247.
14. FDA (2013h) Package insert. GAZYVA (Obinutuzumab). FDA application BLA 125486.
15. FDA (2013i) Package insert. GILOTRIF (Afatinib). FDA application NDA 201192.
16. FDA (2013j) Package insert. IMBRUVICA (Ibrutinib). FDA application NDA 205552.
17. FDA (2013k) Package insert. INVOKANA (Canagliflozin). FDA application NDA 204042.
18. FDA (2013l) Package insert. KADCYLA (Ado-trastuzumab emtansine). FDA application BLA 125427.
19. FDA (2013m) Package insert. KYNAMRO (Mipomersen). FDA application NDA 203568.
20. FDA (2013n) Package insert. LUZU (Luliconazole). FDA application NDA 204153.
21. FDA (2013o) Package insert. LYMPHOSEEK (Technetium Tc-99M Tilmanocept). FDA application NDA 202207.
22. FDA (2013p) Package insert. MEKINIST (Trametinib). FDA application NDA 204114.
23. FDA (2013q) Package insert. NESINA (Alogliptin). FDA application NDA 022271.
24. FDA (2013r) Package insert. OLYSIO (Simeprevir). FDA application NDA 205123.
25. FDA (2013s) Package insert. OPSUMIT (Macitentan). FDA application NDA 204410.
26. FDA (2013t) Package insert. OSPHENA (Ospemifene). FDA application NDA 203505.
27. FDA (2013u) Package insert. POMALYST (Pomalidomide). FDA application NDA 204026.
28. FDA (2013v) Package insert. SOVALDI (Sofosbuvir). FDA application NDA 204671.
29. FDA (2013w) Package insert. TAFINLAR (Dabrafenib). FDA application NDA 202806.
30. FDA (2013x) Package insert. TECFIDERA (Dimethyl fumarate). FDA application NDA 204063.
31. FDA (2013y) Package insert. TIVICAY (Dolutegravir). FDA application NDA 204790.
32. FDA (2013z) Package insert. VIZAMYL (Flutemetammol F18 injection). FDA application NDA 203137.
33. FDA (2013aa) Package insert. XOFIGO (Radium Ra-223 dichloride). FDA application NDA 203971.
34. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
35. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, et al. (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662-670.
36. Huang SM, Zhang L, and Giacomini KM (2010) The International Transporter Consortium: a collaborative group of scientists from academia, industry, and the FDA. Clin Pharmacol Ther 87:32-36.
37. Shen L, Ahmad S, Park S, DeMaio W, Oganesian A, Hultin T, Scatina J, Bungay P, and Chandrasekaran A (2010) In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos 38:1471-1479.
38. Tweedie D, Polli JW, Berglund EG, Huang SM, Zhang L, Poirier A, Chu X, and Feng B, on behalf of the International Transporter Consortium; International Transporter Consortium (2013) Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium. Clin Pharmacol Ther 94:113-125.
39. Zhao P, Rowland M, and Huang SM (2012) Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther 92:17-20.